Candel Therapeutics, Inc. CADL Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Candel Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The official record: Candel Therapeutics, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Candel Therapeutics, Inc.'s net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Candel Therapeutics, Inc.'s net change in cash?
- Candel Therapeutics, Inc. (CADL) reported net change in cash of $75.1M in Q1 2026.
- How has Candel Therapeutics, Inc.'s net change in cash changed year-over-year?
- Candel Therapeutics, Inc.'s net change in cash increased by 816.0% year-over-year, from -$10.49M to $75.1M.
- What is the long-term trend for Candel Therapeutics, Inc.'s net change in cash?
- Over 3 years (2022 to 2025), Candel Therapeutics, Inc.'s net change in cash has grown at a 10.6% compound annual growth rate (CAGR), from -$12.74M to $17.23M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.